ASCO 2016: More excitement about daratumumab (Darzalex®), and tremendous interest in value and costs
Week in Review
The value of a year of life and the ICER report
Week in Review
Myeloma Experts, Not Bureaucrats, Should Create Treatment Recommendations for Patients
Week in Review
ICER Report: Could a flawed approach to cost-effectiveness assessment put patients at risk?
Week in Review




